Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in an ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax beats Q2 expectations with Heplisav-B driving growth. Click here for a full investment analysis of DVAX stock.

Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax's two-dose adult ...

Dynavax's CpG 1018 adjuvant revenues have hit a brick wall. In Dynavax's halcyon days COVID was running hot and it sold its CpG 1018 adjuvant to diverse vaccine companies around the world.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2025 financial results ...

Ryan Spencer, CEO of Dynavax, poses for a photo at the Dynavax office in Emeryville, Calif. on February 13, 2024.

Dynavax reported sales for the vaccine of $11.5 million, an 8.5% year-over-year increase. The company said that its market share in targeted accounts jumped to 26% in Q4 from 20% in the prior-year ...